ESMO胃癌研究新进展选编.pptx

2014 ESMO 胃癌研究新进展罗氏医学部 GC MSL Team;声 明;? 围手术期-?630 632 ? 靶向-?LBA15 615O ? 晚期 – 一线：646 – 后线：657 ? HER2- 629 642 656 ? Biomarker- 626 643 648 650; Qun Zhao, Yong Li, Jun Wang, etc. Forth Hospital of Hebei Medical University, Third surgery department, Hebei, China ;研究背景和目的;研究设计;入组标准;患者基线特征;结果;同步放化疗的毒副反应;围手术期并发症;研究结论;C. Mariette1, G. Piessen1, C. Monterymard2, D. Pezet3, A. Ferru4, M. Baconnier5, X. Adhoute6, D. Tavan7,C. Lepage8, O. Bouché9 1 Department of Digestive and Oncological Surgery, Claude Huriez University, Lille, FRANCE 2 Biostatistics, FFCD, Dijon, FRANCE 3 Department of Surgery, University Hospital, Clermont-Ferrand, FRANCE 4 Department of Oncology, University Hospital, Poitiers, FRANCE 5 Department of Gastroenterology, General Hospital, Annecy, FRANCE 6 Department of Gastroenterology, St Joseph General Hospital, Marseille, FRANCE 7 Department of Gastroenterology, Caluire and Cuire Clinic, Caluire et Cuire, FRANCE 8 Hepatogastroenterology Department, University Hospital, Dijon, FRANCE 9 Gastroenterology and Digestive Oncology, Hopital Robert Debré, Reims, FRANCE;研究背景;研究设计;统计方法;研究结果;研究结果——主要终点;研究结果——次要终点;研究结论;? 围手术期-?630 632 ? 靶向-?LBA15 615O ? 晚期 – 一线：646 – 后线：657 ? HER2- 629 642 656 ? Biomarker- 626 643 648 650;Kei Muro,1 Yung-Jue Bang,2 Veena Shankaran, 3 Ravit Geva,4 et al. 1Department Of Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP 2Internal Medicine, Seoul National University Hospital, 110-744 - Seoul/KR 3Medical Oncology, University of Washinton, Seattle/US 4Oncology, Tel-Aviv Sourasky Medical Center, Tel Aviv/IL;PD-L1通路与免疫监视;PD-L1和PD-L2在胃癌中表达升高;Pembrolizumab (MK-3475)是一种人源化IgG4，高度选择的抗PD-1抗体;KEYNOTE-012（NC：Pembrolizumab在PD-L1+进展期实体瘤患者中多队列Ib期研究;复发或转移性胃或胃食管结合部腺癌 ECOG 0-1 PD-L1+肿瘤a 未经过系统类固醇治疗 无自身免疫系统疾病（活动或有相关病史） 无活动性脑转移;患者基线特征;发生率5%治疗相关不良事件;3-5级治疗相关a不良事件;抗瘤疗效（RECIST v1.1，研究者评估）;与基线比较肿瘤测量变化最大百分比;药物暴露及缓解时间;结 论;;研究背景;转移性，可评估胃/胃食管交界处腺癌 （n=195） ;研究终点统计假设;研究过程;患者基线情况（1）;患者基线特征（2）;主要研究终点: PFS (独立评审);Min-Hee Ryu